A Dose of Perspective: A Multinational Survey of Patient and Clinician Views on Combination Therapy in CKD.
Nasir A Shah, Rui Du, Brendon L Neuen...
https://pubmed.ncbi.nlm.nih.gov/42228487/Actively Recruiting
Led by The George Institute · Updated on 2026-10-05
2000
Participants Needed
51
Research Sites
N/A
Total Duration
Researchers are conducting an international, multi-center Phase III trial called CAPTIVATE to study treatments for chronic kidney disease CKD, which affects over 800 million people worldwide and can lead to kidney failure and other serious health problems. The trial aims to identify the best single or combined treatments that can slow CKD progression and reduce the number of people developing kidney failure. CAPTIVATE uses an adaptive platform design allowing multiple therapies to be tested efficiently within a common framework, with the flexibility to add or remove treatments over time. Participants may join one or more treatment domains and receive each study treatment for 2 years. Treatments under study include finerenone tablets taken once daily and semaglutide injections given once weekly, along with their matching placebos. Participants will attend scheduled study visits at approximately 1 month, 3 months, 6 months, 12 months, 18 months, and 2 years after starting treatment, with a final visit one month after treatment ends. The trial is ongoing and will continue recruiting for several years. During the study, participants undergo blood and urine tests, safety checks, and assessments of treatment adherence at regular visits. The research team collects information on overall health status every 5 years. The primary outcomes focus on treatment effects measured from randomization through week 108, with various secondary outcomes tracked throughout the study. Safety is monitored continuously, and participants remain under their usual care alongside the trial procedures.
CONDITIONS
The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect
E
Enmoore Lin
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
The George Institute
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are assessed to confirm eligibility for the trial and specific treatment domains.
Initial screening visit
Duration - 2 years
Participants receive assigned study treatments, such as finerenone tablets daily or semaglutide injections weekly, or matching placebos, for up to 2 years.
Study visits at 1, 3, 6, 12, 18, and 24 months after treatment start, plus a final visit one month after treatment ends
Duration - Ongoing every 5 years
Participants' overall health status is checked every 5 years to monitor long-term outcomes.
Periodic health assessments
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
FACTORIAL
Primary Purpose
TREATMENT
Number of Arms
4
Have more questions? Get in touch with our team for quick support
Nasir A Shah, Rui Du, Brendon L Neuen...
https://pubmed.ncbi.nlm.nih.gov/42228487/Hiddo J L Heerspink, Matthias Kretzler
https://pubmed.ncbi.nlm.nih.gov/39248631/Sradha S Kotwal, Vlado Perkovic, Meg J Jardine...
https://pubmed.ncbi.nlm.nih.gov/39661388/Emily K Yeung, Janani Rangaswami, Katherine R Tuttle...
https://pubmed.ncbi.nlm.nih.gov/42335037/The George Institute
Lead Sponsor